{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:42:07Z","timestamp":1775083327665,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Recent studies have reported an association between Cytotoxic T-lymphocyte antigen-4 (CTLA-4) polymorphisms and hematologic malignancy susceptibility, while the results remain inconsistent. Hence, we performed a meta-analysis to investigate the association between CTLA-4 polymorphisms with hematologic malignancy susceptibility.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive and systematic search of Cochrane Library, PubMed, Embase databases was performed up to Sep. 20, 2024. The pooled odds ratio (OR) and its 95% confidence interval (CI) were used to determine the strength of the association between CTLA-4 polymorphisms and hematologic malignancy susceptibility. Statistical analysis was performed in STATA 12.0.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 13 studies concerning the CTLA-4 49A\/G, CTLA-4 60A\/G, CTLA-4 318T\/C, CTLA-4 1661A\/G, and CTLA-4 319C\/T polymorphisms were included in the meta-analysis. The pooled results suggested the CTLA-4 49A\/G polymorphism was significantly associated with an increased hematologic malignancy risk (AA vs. GA+GG: OR = 1.77, 95% CI = 1.56-2.02), especially in NHL, multiple myeloma, and leukemia. Similarly, CTLA-4 319C\/T polymorphism was found to be associated with decreased chronic lymphocytic leukemia risk. There was no significant association between the CTLA-4 60A\/G, 318T\/C, and 1661A\/G polymorphism and hematologic malignancy risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CTLA-4 49A\/G and 319C\/T polymorphisms were associated with hematologic malignancy susceptibility.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1467740","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T05:10:20Z","timestamp":1728623420000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of CTLA-4 polymorphisms with hematologic malignancy susceptibility: a meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Xuefen","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.8644","article-title":"Germline genetic predisposition to hematologic Malignancy","volume":"35","author":"Furutani","year":"2017","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-021-06502-2","article-title":"Critical illness in patients with hematologic Malignancy: a population-based cohort study","volume":"47","author":"Ferreyro","year":"2021","journal-title":"Intensive Care Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups 1990 to 2017: A systematic analysis for the global burden of disease study","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2960","article-title":"The global, regional, and national burden of adult lip, oral, and pharyngeal cancer in 204 countries and territories: A systematic analysis for the global burden of disease study 2019","volume":"9","author":"Gbd Lip","year":"2023","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.8954","article-title":"Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment","volume":"26","author":"Fong","year":"2008","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semcancer.2020.06.016","article-title":"Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer","volume":"79","author":"Gaynor","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.05.019","article-title":"TP53 mutation as potential negative predictor for response of anti-CTLA-4 therapy in metastatic melanoma","volume":"32","author":"Xiao","year":"2018","journal-title":"EBioMedicine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/molecules26020253","article-title":"Peptide blocking CTLA-4 and B7-1 interaction","volume":"26","author":"Podlesnykh","year":"2021","journal-title":"Molecules"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2010.10.001","article-title":"Polymorphisms of the CTLA4 gene and kidney transplant rejection in Korean patients","volume":"24","author":"Kim","year":"2010","journal-title":"Transpl Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0136","article-title":"Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome","volume":"2","author":"Charbonneau","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23164","article-title":"Impact of the cytotoxic T-lymphocyte associated antigen-4 rs231775 A\/G polymorphism on cancer risk","volume":"9","author":"Pan","year":"2023","journal-title":"Heliyon"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.14715\/cmb\/2023.69.4.5","article-title":"Association between thyroid cancer and CTLA-4 gene polymorphisms","volume":"69","author":"Sun","year":"2023","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20045","article-title":"Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin's lymphoma","volume":"76","author":"Monne","year":"2004","journal-title":"Am J Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05525.x","article-title":"Genetic analysis of the 2q33 region containing CD28-CTLA4-ICOS genes: association with non-Hodgkin's lymphoma","volume":"129","author":"Piras","year":"2005","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.5434","article-title":"Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma","volume":"24","author":"Cheng","year":"2006","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12308-008-0003-y","article-title":"Analysis of single nucleotide polymorphisms in the FAS and CTLA-4 genes of peripheral T-cell lymphomas","volume":"1","author":"Bonzheim","year":"2008","journal-title":"J Hematop"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10278","article-title":"CTLA-4 exon 1 polymorphism in patients with autoimmune blood disorders","volume":"72","author":"Pavkovic","year":"2003","journal-title":"Am J Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.humimm.2008.01.014","article-title":"Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population","volume":"69","author":"Suwalska","year":"2008","journal-title":"Hum Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-011-9431-6","article-title":"Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population","volume":"18","author":"Karabon","year":"2012","journal-title":"Pathol Oncol Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2013.08.011","article-title":"Genetic variations in CTLA-4, TNF-alpha, and LTA and susceptibility to T-cell lymphoma in a Chinese population","volume":"37","author":"Liu","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.820294","article-title":"Association of cytotoxic T-lymphocyte antigen 4 genetic polymorphism, hepatitis C viral infection and B-cell non-Hodgkin lymphoma: an Egyptian study","volume":"55","author":"Khorshied","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12885-015-1506-4","article-title":"LTA + 252A > G polymorphism is associated with risk of nasal NK\/T-cell lymphoma in a Chinese population: a case-control study","volume":"15","author":"Cheng","year":"2015","journal-title":"BMC Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2017.0176","article-title":"Genetic variation of costimulatory molecules, including cytotoxic T-lymphocyte antigen 4, inducible T-cell costimulator, cluster differentiation 28, and programmed cell death 1 genes, in Iranian patients with leukemia","volume":"18","author":"Ramzi","year":"2020","journal-title":"Exp Clin Transplant"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2021.103330","article-title":"Genetic polymorphisms and risk of MALT lymphoma in Greek population","volume":"70","author":"Velissari","year":"2022","journal-title":"Curr Res Transl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2329024","article-title":"TIM3 and CTLA4 immune checkpoint polymorphisms are associated with acute myeloid leukemia in Saudi Arabia","volume":"29","author":"Alqahtani","year":"2024","journal-title":"Hematology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.11.002","article-title":"CTLA-4 and autoimmunity: new twists in the tale","volume":"36","author":"Walker","year":"2015","journal-title":"Trends Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-051122-100856","article-title":"Epigenomic characterization of lymphoid neoplasms","volume":"19","author":"Duran-Ferrer","year":"2024","journal-title":"Annu Rev Pathol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1233376","article-title":"Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy","volume":"13","author":"Lee","year":"2023","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106633","article-title":"Comprehensive analysis of CTLA-4 in the tumor immune microenvironment of 33 cancer types","volume":"85","author":"Zhang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-022-00404-3","article-title":"Burkitt lymphoma","volume":"8","author":"Lopez","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01904-w","article-title":"Therapeutic challenges in peripheral T-cell lymphoma","volume":"23","author":"Luan","year":"2024","journal-title":"Mol Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2021.12.029","article-title":"Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma","volume":"164","author":"Brivio","year":"2022","journal-title":"Eur J Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1467740\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T05:10:21Z","timestamp":1728623421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1467740\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":34,"alternative-id":["10.3389\/fonc.2024.1467740"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1467740","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]},"article-number":"1467740"}}